SCHEMBL207176

SCHEMBL207176

Fc1ccc(-c2csc(Nc3ccc(Cc4ccccc4)cc3)n2)c(F)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGER Q15109 2/20 0.61
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
VCP P55072 1/20 0.55
PLAU P00749 1/20 0.53
NPY5R Q15761 1/20 0.53
MAOA P21397 3/20 0.51
MAOB P27338 3/20 0.51
TYR P14679 1/20 0.49
MPL P40238 2/20 0.48
MAPT P10636 3/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
POLB P06746 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
SIRT5 Q9NXA8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206837 0.91 AGER (0.69) AGERNPC1RAB9AMEN1KMT2A
SCHEMBL29276772 0.89 AGER (0.75) AGERNPC1RAB9AMEN1KMT2A
SCHEMBL19851004 0.86 AGER (0.70) AGERNPC1RAB9AMEN1KMT2A
SCHEMBL208100 0.83 NPY5R (0.78) NPC1RAB9AMEN1KMT2AVCP
SCHEMBL13193326 0.82 AGER (0.57) AGERNPC1RAB9AMEN1KMT2A
SCHEMBL205667 0.81 AGER (0.55) AGERNPC1RAB9AMEN1KMT2A
SCHEMBL207028 0.81 AGER (0.67) AGERNPC1RAB9AMEN1KMT2A
SCHEMBL28908960 0.80 AGER (0.62) AGERNPC1RAB9AMEN1KMT2A
SCHEMBL29276768 0.79 NPY5R (0.66) AGERNPC1RAB9AMEN1KMT2A
SCHEMBL205404 0.79 VCP (0.65) AGERNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US claimed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 AGER 3576/4885NPC1 62/4885RAB9A 1357/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 AGER 3576/4885NPC1 62/4885RAB9A 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.